ロケット・ワン
RKTO
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.17 | $0 | -$3M |
| 2025 Q4 | -0.17 | $0 | -$2M |
| 2025 Q3 | -0.30 | $0 | -$2M |
| 2025 Q2 | -0.17 | $0 | -$2M |
| 2025 Q1 | -0.36 | $0 | -$3M |
| 2024 Q4 | -0.33 | $0 | -$2M |
| 2024 Q3 | -0.31 | $0 | -$2M |
| 2024 Q2 | -0.24 | $0 | -$2M |